Cosmos Health Announces Open Market Stock Purchases By The CEO; Mr Greg Siokas, Intends To Purchase An Aggregate Of Up To $3M In Common Shares Of The Company In The Open Market Through December 31, 2024
Cosmos Health Announces Open Market Stock Purchases By The CEO; Mr Greg Siokas, Intends To Purchase An Aggregate Of Up To $3M In Common Shares Of The Company In The Open Market Through December 31, 2024
Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Mr Greg Siokas, intends to purchase an aggregate of up to $3 million in common shares of the Company in the open market through December 31, 2024.
從事創新研發的多元化、垂直整合的全球醫療保健集團Cosmos Health Inc.（“Cosmos Health” 或 “公司”）（納斯達克股票代碼：COSM）今天宣佈，其首席執行官格雷格·西奧卡斯打算購買該公司總計不超過300萬美元的普通股公開市場將持續到2024年12月31日。
So far in 2023, Mr. Siokas has already purchased Cosmos Health shares worth approximately $1 million through various dates via privately negotiated transactions and by participating in a share capital increase. He now intends to increase his stake in the Company through open market purchases.
2023年到目前爲止，西奧卡斯先生已經通過私下談判交易和參與股本增加，在不同日期購買了價值約100萬美元的Cosmos Health股票。他現在打算通過公開市場收購來增加他在該公司的股份。
Mr Siokas may purchase shares from time to time through open market transactions in accordance with applicable securities laws and other restrictions. The timing and total amount of stock purchases will depend on market conditions, corporate and regulatory requirements, prevailing stock prices and other considerations.
根據適用的證券法和其他限制，西奧卡斯先生可以不時通過公開市場交易購買股票。股票購買的時間和總金額將取決於市場狀況、公司和監管要求、現行股票價格和其他考慮因素。
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "As we have repeatedly stated, we believe our shares are undervalued relative to our growth prospects and progress to date. Today, I am pleased to announce my intention to purchase up to $3 million worth of our common shares. Based on recent share prices, this represents approximately 20% of our market capitalization, assuming full utilization.
Cosmos Health首席執行官格雷格·西奧卡斯表示：“正如我們反覆指出的那樣，相對於我們的增長前景和迄今爲止的進展，我們認爲我們的股票被低估了。今天，我很高興地宣佈，我打算購買價值不超過300萬美元的普通股。根據最近的股價，假設充分利用，這約佔我們市值的20％。
"Since inception, I have invested more than $15 million in Cosmos and am committed to continue supporting the Company. Given the current trading price of our stock, I believe it is prudent to purchase shares in the open market and increase my stake in Cosmos during this exciting period. Our innovative R&D projects, anticipated entry into AI-drug repurposing, the planned spinoff of our R&D department into a standalone, publicly-listed biotech company, and the international growth of our brands make this a strategic time for such an investment."
“自成立以來，我已向Cosmos投資了超過1500萬美元，並承諾繼續爲公司提供支持。鑑於我們股票目前的交易價格，我認爲謹慎的做法是在這個激動人心的時期在公開市場上購買股票並增加我在Cosmos的股份。我們的創新研發項目、預計將進入人工智能藥物再利用、計劃將我們的研發部門分拆爲一家獨立的上市生物技術公司，以及我們品牌的國際增長，使之成爲此類投資的戰略時期。”
譯文內容由第三人軟體翻譯。